恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

老年hcc患者deb-ag捕鱼平台

文字: 2018-7-2    浏览次数:896    

abstract:the aim of this study was to explore the difference of liver function change, safety profiles and efficacy of drug-eluting bead transarterial chemoembolization(deb-tace) therapy between elderly and middle-aged hepatocellular carcinoma(hcc) patients. 91 hcc patients were enrolled in this prospective cohort study.they were treated by deb-tace therapy and divided into elderly group (age >=65 years, n=30) and middle-aged group (age < 65 years, n=61), liver function, safety profiles and treatment response were recorded. no difference of liver function was found between two groups before operation and at 1 week post deb-tace treatment. while the portion of abnormal total protein (tp) in elderly group was elevated than that in middle age group at 1-3 months after operation. during operation, elderly group presented with raised incidence of vomiting compared with middle-aged group, whereas elderly patients displayed lower incidence of pain than middle-aged patients at 1 month post treatment. no other difference of safety profiles was found between the two groups. at 1-3 months after treatment, elderly patients achieved complete response (cr) of 26.7% and overall response rate (orr) of 93.3%, meanwhile, middle-aged patients obtained cr of 23.0% and orr of 90.2%. no difference of cr and orr was found between elderly and middle-aged patients, in addition, no difference of os was observed between the two groups. in conclusion, deb-tace therapy was well tolerated in elderly hcc patients, and it possessed equal efficacy in elderly patients compared with middle-aged patients.


摘要:本研究的目的是在老年和中年肝细胞癌(hcc)患者中,对比药物洗脱微球栓塞化疗(deb-tace)的肝功能改变,安全性和疗效的差异。这项前瞻性队列研究纳入91名hcc患者,这些患者接受deb-tace治疗,被分为老年组(≥65岁,n=30)和中年组(年龄<65岁,n=61),记录肝功能,安全性和治疗反应。在治疗前和deb-tace治疗1周后,两组的肝功能未发现差异;但老年组治疗后1~3个月的总蛋白水平异常的患者比例较中年组增高。deb-tace期间,老年组发生呕吐的比例更高,治疗后1个月疼痛的发生率更低。其他安全性数据两组间未发现差异。治疗后1-3个月,老年患者中完全缓解率(cr)为26.7%,客观缓解率(orr)为93.3%,中年患者这两个比例分别为23.0%和90.2%。老年患者和中年患者的cr和orr未发现差异。另外两组的os也无显著差异。总之,deb-tace在老年hcc患者中耐受性良好,与中年患者相比,治疗的疗效相当。